MUW80O1734624671582_RLS

Name : Deepika Naik (55Y/F)
Date : 19 Dec 2024
Test Asked : Aarogyam 1.3 With Utsh
Report Status: Complete Report

PROCESSED AT :
Thyrocare
H. NO. 1-9-645,Vidyanagar,
Adikmet Road,Near SBH,
Hyderabad-500 044
NAME : DEEPIKA NAIK (55Y/F) SAMPLE COLLECTED AT :

REF. BY : SELF
(4001043671),SHARMA HEALTHCARE SERVICE
TEST ASKED : AAROGYAM 1.3 WITH UTSH ,New Link Rd, Motilal Nagar II, Goregaon West,
Mumbai, Maharashtra, India,400104
Report Availability Summary

Note: Please refer to the table below for status of your tests.
17 Ready 0 Ready with Cancellation 0 Processing 0 Cancelled in Lab
TEST DETAILS REPORT STATUS
AAROGYAM 1.3 WITH UTSH Ready
CYSTATIN C Ready
HOMOCYSTEINE Ready
HIGH SENSITIVITY C-REACTIVE PROTEIN (HS-CRP) Ready
Lipoprotein (a) [Lp(a)] Ready
SERUM COPPER Ready
SERUM ZINC Ready
TESTOSTERONE Ready
HBA PROFILE Ready
HEMOGRAM - 6 PART (DIFF) Ready
LIVER FUNCTION TESTS Ready
ELEMENTS 22 (TOXIC AND NUTRIENTS) Ready
IRON DEFICIENCY PROFILE Ready
KIDPRO Ready
LIPID PROFILE Ready
T3-T4-USTSH Ready
VITAMIN D TOTAL AND B12 COMBO Ready
APOLIPROTEIN RATIO Ready

PROCESSED AT :
Thyrocare
Hyderabad-500 044

REF. BY : SELF (4001043671),SHARMA HEALTHCARE SERVICE ,New
TEST ASKED : AAROGYAM 1.3 WITH UTSH Link Rd, Motilal Nagar II, Goregaon West, Mumbai,
Maharashtra, India,400104
Summary Report
Tests outside reference range
TEST NAME OBSERVED VALUE UNITS Bio. Ref. Interval.
CARDIAC RISK MARKERS
HIGH SENSITIVITY C-REACTIVE PROTEIN (HS-CRP) 8.29 mg/L <3
HOMOCYSTEINE 22.69 µmol/L <15
TRIG / HDL RATIO 5.79 Ratio < 3.12
COMPLETE HEMOGRAM
EOSINOPHILS 0.8 % 1-6
HEMATOCRIT(PCV) 46.5 % 36.0-46.0
LYMPHOCYTES - ABSOLUTE COUNT 3.47 X 10³ / µL 1.0-3.0
MEAN CORP.HEMO.CONC(MCHC) 29.2 g/dL 31.5-34.5
MEAN CORPUSCULAR HEMOGLOBIN(MCH) 26.7 pq 27.0-32.0
NEUTROPHILS - ABSOLUTE COUNT 8.1 X 10³ / µL 2.0-7.0
RED CELL DISTRIBUTION WIDTH - SD(RDW-SD) 47 fL 39.0-46.0
TOTAL LEUCOCYTES COUNT (WBC) 11.98 X 10³ / µL 4.0 - 10.0
TOTAL RBC 5.09 X 10^6/µL 3.8-4.8
DIABETES
AVERAGE BLOOD GLUCOSE (ABG) 275 mg/dL 90-120
HbA1c 11.2 % < 5.7
HORMONE
TESTOSTERONE < 2.5 ng/dL 6 - 82
LIPID
LDL CHOLESTEROL - DIRECT 104 mg/dL < 100
TRIGLYCERIDES 249 mg/dL < 150
VLDL CHOLESTEROL 49.8 mg/dL 5 - 40
RENAL
CREATININE - SERUM 0.51 mg/dL 0.55-1.02
TOXIC ELEMENTS
BERYLLIUM 0.05 µg/L 0.10 - 0.80
VITAMINS
25-OH VITAMIN D (TOTAL) 15 ng/mL 30-100
VITAMIN B-12 178 pg/mL 197-771
Disclaimer: The above listed is the summary of the parameters with values outside the BRI. For detailed report values,
parameter correlation and clinical interpretation, kindly refer to the same in subsequent pages.
PROCESSED AT :
Thyrocare
Hyderabad-500 044

REF. BY : SELF (4001043671),SHARMA HEALTHCARE SERVICE
,New Link Rd, Motilal Nagar II, Goregaon West,
TEST ASKED : AAROGYAM 1.3 WITH UTSH
TEST NAME TECHNOLOGY VALUE UNITS

HOMOCYSTEINE PHOTOMETRY 22.69 µmol/L
Bio. Ref. Interval. :-
Normal Levels : <15 µmol/L

Mild Hyperhomocysteinemia : 15-30 µmol/L
Moderate Hyperhomocysteinemia : 30-100 µmol/L
Severe Hyperhomocysteinemia : >100 µmol/L
Clinical Significance:
Homocysteine is linked to increased risk of premature coronary artery disease, stroke and thromboembolism. Moreover,
alzheimers disease, osteoporosis, venous thrombosis, schizophrenia, cognitive deficiency and pregnancy complications also
elevates Homocysteine levels. The results should be interpreted in conjunction with clinical history and other findings.
High Values:
Elevated homocysteine levels might be due to increasing age, genetic traits, drugs, renal dysfunction and dietary deficiency of
vitamins or smoking. To lower your homocysteine, eat more green vegetables, stop smoking, alcohol. Folic acid helps lowering
elevated levels.
Specifications:
Kit Validation Reference:
Eikelboom JW, et al Ann Intern Med 131 : 363-75 (1999)
https://www.healthline.com/health/homocysteine-levels
Please correlate with clinical conditions.

Method:- SMALL MOLECULE CAPTURE TECHNOLOGY (SMT)
Sample Collected on (SCT) : 19 Dec 2024 21:40

Sample Received on (SRT) : 20 Dec 2024 00:51
Report Released on (RRT) : 20 Dec 2024 05:13
Sample Type : SERUM
Dr Amulya MD (Path)
Labcode : 1912107909/MUW80
Barcode : DD717289 Page : 1 of 19
PROCESSED AT :
Thyrocare
Hyderabad-500 044


CYSTATIN C IMMUNOTURBIDIMETRY 0.79 mg/L
<= 60 years: <= 1.03 mg/L

> 60 years : < 1.50 mg/L
Clinical significance
Cystatin c, is a small 13-kda protein and is a member of the cysteine proteinase inhibitor family, it is produced at a constant rate
by all nucleated cells. Due to its small size it is freely filtered by the glomerulus and is not secreted but is fully reabsorbed and
broken down by the renal tubules. This means that the primary determinate of blood Cystatin c levels is the rate at which it is
filtered at the glomerulus making it an excellent gfr marker. Cystatin c is also a marker of inflammation and like many other
markers of inflammation; its serum concentration may be higher in patients with decreased renal clearance. There is mounting
evidence, however, that Cystatin c may be a predictor of adverse outcomes independent of renal function with its higher
sensitivity to detect a reduced GFR than Creatinine determination, also in the so-called “Creatinine-blind” range. Thus, Cystatin c
is suggested to be a better marker for GFR than the ubiquitous serum Creatinine.
Reference
1. Barrett aj, Davies me, Grubb a. the place of human gamma-trace (Cystatin c) among the cysteine proteinase inhibitors. Biochem
biophys res common 1984; 120: 631-6.
2. Grubb a. diagnostic value of analysis of Cystatin c and protein HC in biological fluids. Clin Nephrol 1992; 38: S20-7.

Method:- LATEX ENHANCED IMMUNOTURBIDIMETRY

Sample Type : SERUM
Dr Amulya MD (Path)
Labcode : 1912107909/MUW80
PROCESSED AT :
Thyrocare
Hyderabad-500 044

REF. BY (4001043671),SHARMA HEALTHCARE SERVICE
: SELF
TEST ASKED : AAROGYAM 1.3 WITH UTSH Mumbai, Maharashtra, India,400104
25-OH VITAMIN D (TOTAL) E.C.L.I.A 15 ng/mL

Bio. Ref. Interval. :
Deficiency : <=20 ng/ml || Insufficiency : 21-29 ng/ml
Sufficiency : >= 30 ng/ml || Toxicity : >100 ng/ml
Vitamin D is a fat soluble vitamin that has been known to help the body absorb and retain calcium and phosphorous; both are critical for building
bone health.
Decrease in vitamin D total levels indicate inadequate exposure of sunlight, dietary deficiency, nephrotic syndrome.
Increase in vitamin D total levels indicate Vitamin D intoxication.
Specifications: Precision: Intra assay (%CV):9.20%, Inter assay (%CV):8.50%

Kit Validation Reference : Holick M. Vtamin D the underappreciated D-Lightful hormone that is important for Skeletal
and cellular health Curr Opin Endocrinol Diabetes 2002:9(1)87-98.
Method : Fully Automated Electrochemiluminescence Compititive Immunoassay

VITAMIN B-12 E.C.L.I.A 178 pg/mL
Normal: 197-771 pg/ml
Clinical significance :
Vitamin B12 or cyanocobalamin, is a complex corrinoid compound found exclusively from animal dietary sources, such as meat, eggs and milk. It
is critical in normal DNA synthesis, which in turn affects erythrocyte maturation and in the formation of myelin sheath. Vitamin-B12 is used to find
out neurological abnormalities and impaired DNA synthesis associated with macrocytic anemias. For diagnostic purpose, results should always be
assessed in conjunction with the patients medical history, clinical examination and other findings.
Specifications: Intra assay (%CV):2.6%, Inter assay (%CV):2.3 %
Kit Validation Reference : Thomas L.Clinical laborator Diagnostics : Use and Assessment of Clinical laboratory Results 1st Edition,TH
Books-Verl-Ges,1998:424-431
Method : Fully Automated Electrochemiluminescence Compititive Immunoassay


Sample Type : SERUM
Labcode : 1912107909/MUW80 Dr Amulya MD (Path)
Barcode : DD717289
Page : 3 of 19
PROCESSED AT :
Thyrocare
Hyderabad-500 044

: SELF
APOLIPOPROTEIN - A1 (APO-A1) IMMUNOTURBIDIMETRY 143 mg/dL

MALE : 86 - 152
FEMALE : 94 - 162
Method : FULLY AUTOMATED RATE IMMUNOTURBIDIMETRY – BECKMAN COULTER

APOLIPOPROTEIN - B (APO-B) IMMUNOTURBIDIMETRY 99 mg/dL
MALE : 56 - 145
FEMALE : 53 - 138
Method : FULLY AUTOMATED RATE IMMUNOTURBIDIMETRY – BECKMAN COULTER

APO B / APO A1 RATIO (APO B/A1) CALCULATED 0.7 Ratio
Male : 0.40 - 1.26
Female : 0.38 - 1.14
Method : Derived from serum Apo A1 and Apo B values


Sample Type : SERUM
Barcode : DD717289
Page : 4 of 19
PROCESSED AT :
Thyrocare
Hyderabad-500 044


HIGH SENSITIVITY C-REACTIVE PROTEIN (HS-CRP) IMMUNOTURBIDIMETRY 8.29 mg/L
< 1.00 - Low Risk

1.00 - 3.00 - Average Risk
>3.00 - 10.00 - High Risk
> 10.00 - Possibly due to Non-Cardiac Inflammation
Disclaimer: Persistent unexplained elevation of HSCRP >10 should be evaluated for non-cardiovascular etiologies such as
infection , active arthritis or concurrent illness.
Clinical significance:
High sensitivity C- reactive Protein ( HSCRP) can be used as an independent risk marker for the identification of Individuals at risk
for future cardiovascular Disease. A coronary artery disease risk assessment should be based on the average of two hs-CRP
tests, ideally taken two weeks apart.

1.Clinical management of laboratory date in medical practice 2003-3004, 207(2003).
2.Tietz : Textbook of Clinical Chemistry and Molecular diagnostics :Second edition :Chapter 47:Page no.1507- 1508.

Method:- FULLY AUTOMATED LATEX AGGLUTINATION – BECKMAN COULTER

Sample Type : SERUM
Dr Amulya MD (Path)
Labcode : 1912107909/MUW80
PROCESSED AT :
Thyrocare
Hyderabad-500 044


Lipoprotein (a) [Lp(a)] IMMUNOTURBIDIMETRY <2 mg/dL
Adults : < 30.0 mg/dl
Determination of LPA may be useful to guide management of individuals with a family history of CHD or with existing disease. The
levels of LPA in the blood depends on genetic factors; The range of variation in a population is relatively large and hence for
diagnostic purpose, results should always be assessed in conjunction with the patient’s medical history, clinical examination and
other findings.
Specifications:
Precision %CV :- Intra assay %CV- 4.55% , Inter assay %CV-0.86 %

Tietz NW,Clinical Guide to Laboratory Tests Philadelphia WB. Saunders 1995 : 442-444

Method:- LATEX ENHANCED IMMUNOTURBIDIMETRY

Sample Type : SERUM
Dr Amulya MD (Path)
Labcode : 1912107909/MUW80
PROCESSED AT :
Thyrocare
Hyderabad-500 044


SERUM COPPER PHOTOMETRY 127.11 µg/dL
Male : 63.5 - 150

Female : 80 - 155
Clinical significance:
Copper is an important trace element and a component of numerous enzymes and proteins involved in energy production,
connective tissue formation, melanin synthesis, iron metabolism, development of central nervous system, angiogenesis as well as
an antioxidant. Deficiency can cause- Malnourishment, cardiovascular disease, anemia & neuropathy, toxicity may be manifested
as acute renal failure, gastroenteritis & chronic liver disease.
Specifications:
Precision: Intra assay (%CV): 1.17, Inter assay (%CV): 2.32.
Kit validation references:

Thomas L. Clinical Laboratory Diagnostics. 1st ed. Frankfurt: TH-Books Verlagsgesellschaft; 1998. p. 337-8

Method:- 3,5-DIBR-PAESA

Sample Type : SERUM
Dr Amulya MD (Path)
Labcode : 1912107909/MUW80
PROCESSED AT :
Thyrocare
Hyderabad-500 044


SERUM ZINC PHOTOMETRY 167.78 µg/dL
52 - 286
Zinc is one of the essential trace elements in the body. Its metalloenzymes play a key rple in protein and nucleic acid synthesis,
gene expression, wound healing, as an antioxidant, etc. Deficiency can cause- Poor wound healing, gastroenteritis, impaired
spermatogenesis, Alzheimer’s disease, etc. Toxicity may be manifested as pancreatitis, gastric ulcer, anemia, pulmonary fibrosis.
Specifications:
Precision: Intra assay (%CV): 2.02, Inter assay (%CV): 2.22.
Kit Validation References:

Thomas L. Clinical Laboratory Diagnostics. 1st ed. Frankfurt: TH-Books Verlagsgesellschaft; 1998. p. 347-9

Method:- NITRO - PAPS

Sample Type : SERUM
Dr Amulya MD (Path)
Labcode : 1912107909/MUW80
PROCESSED AT :
Thyrocare
Hyderabad-500 044


TESTOSTERONE E.C.L.I.A < 2.5 ng/dL
6 - 82
Clinical Significance: Clinical evaluation of serum testosterone, along with serum LH, assists in evaluation of Hypogonadal males.
Major causes of lowered testosterone in males include Hypogonadotropic hypogonadism, testicular failure Hyperprolactinema,
Hypopituitarism some types of liver and kidney diseases and critical illness.
Specifications: Precision: Intra assay (%CV): 11.50 %, Inter assay (%CV): 5.70%; Sensitivity: 7 ng/dL.
Kit Validation Reference: Wilson JD Foster DW (Eds) Williams Textbook of Endocrinology 8th Edition WB Saunders Piladelphia
Pennsylvania.
Note : The Biological Reference Range mentioned is specific to the age group and gender. Kindly correlate clinically.

Method:- Fully Automated Electrochemiluminescence Compititive Immunoassay

Sample Type : SERUM
Dr Amulya MD (Path)
Labcode : 1912107909/MUW80
PROCESSED AT :
Thyrocare
Hyderabad-500 044

: SELF
IRON PHOTOMETRY 83.08 µg/dL

Male : 65 - 175
Female : 50 - 170
Method : Ferrozine method without deproteinization

TOTAL IRON BINDING CAPACITY (TIBC) PHOTOMETRY 346.08 µg/dL
Male: 225 - 535 µg/dl Female: 215 - 535 µg/dl
Method : Spectrophotometric Assay

% TRANSFERRIN SATURATION CALCULATED 24.01 %
13 - 45
Method : Derived from IRON and TIBC values

UNSAT.IRON-BINDING CAPACITY(UIBC) PHOTOMETRY 263 µg/dL
162 - 368
Method : SPECTROPHOTOMETRIC ASSAY


Sample Type : SERUM
Barcode : DD717289
Page : 10 of 19
PROCESSED AT :
Thyrocare
Hyderabad-500 044

REF. BY (4001043671),SHARMA HEALTHCARE SERVICE ,New
: SELF
Link Rd, Motilal Nagar II, Goregaon West, Mumbai,
TEST ASKED : AAROGYAM 1.3 WITH UTSH Maharashtra, India,400104
TEST NAME TECHNOLOGY VALUE UNITS Bio. Ref. Interval.

TOTAL CHOLESTEROL PHOTOMETRY 179 mg/dL < 200
HDL CHOLESTEROL - DIRECT PHOTOMETRY 43 mg/dL 40-60
TRIG / HDL RATIO CALCULATED 5.79 Ratio < 3.12
TRIGLYCERIDES PHOTOMETRY 249 mg/dL < 150
HDL / LDL RATIO CALCULATED 0.41 Ratio > 0.40
LDL CHOLESTEROL - DIRECT PHOTOMETRY 104 mg/dL < 100
TC/ HDL CHOLESTEROL RATIO CALCULATED 4.2 Ratio 3-5
LDL / HDL RATIO CALCULATED 2.4 Ratio 1.5-3.5
VLDL CHOLESTEROL CALCULATED 49.8 mg/dL 5 - 40
NON-HDL CHOLESTEROL CALCULATED 136.38 mg/dL < 160
Method :
CHOL - Cholesterol Oxidase, Esterase, Peroxidase
HCHO - Direct Enzymatic Colorimetric
TRI/H - Derived from TRIG and HDL Values
TRIG - Enzymatic, End Point
HD/LD - Derived from HDL and LDL values.
LDL - Direct Measure
TC/H - Derived from serum Cholesterol and Hdl values
LDL/ - Derived from serum HDL and LDL Values
VLDL - Derived from serum Triglyceride values
NHDL - Derived from serum Cholesterol and HDL values
*REFERENCE RANGES AS PER NCEP ATP III GUIDELINES:
TOTAL CHOLESTEROL (mg/dl) HDL (mg/dl) LDL (mg/dl) TRIGLYCERIDES (mg/dl)
DESIRABLE <200 LOW <40 OPTIMAL <100 NORMAL <150

BORDERLINE HIGH 200-239 HIGH >60 NEAR OPTIMAL 100-129 BORDERLINE HIGH 150-199
BORDERLINE HIGH
HIGH >240 130-159 HIGH 200-499
HIGH 160-189 VERY HIGH >500
VERY HIGH >190
Alert !!! 10-12 hours fasting is mandatory for lipid parameters. If not, values might fluctuate.

Sample Type : SERUM

PROCESSED AT :
Thyrocare
Hyderabad-500 044

: SELF

ALKALINE PHOSPHATASE PHOTOMETRY 114.96 U/L 45-129
BILIRUBIN -DIRECT PHOTOMETRY 0.07 mg/dL < 0.3
BILIRUBIN - TOTAL PHOTOMETRY 0.53 mg/dL 0.3-1.2
BILIRUBIN (INDIRECT) CALCULATED 0.46 mg/dL 0-0.9
GAMMA GLUTAMYL TRANSFERASE (GGT) PHOTOMETRY 30.33 U/L < 38
SGOT / SGPT RATIO CALCULATED 1 Ratio <2
ASPARTATE AMINOTRANSFERASE (SGOT ) PHOTOMETRY 21.85 U/L < 31
ALANINE TRANSAMINASE (SGPT) PHOTOMETRY 21.83 U/L < 34
PROTEIN - TOTAL PHOTOMETRY 7.08 gm/dL 5.7-8.2
ALBUMIN - SERUM PHOTOMETRY 4.11 gm/dL 3.2-4.8
SERUM GLOBULIN CALCULATED 2.97 gm/dL 2.5-3.4
SERUM ALB/GLOBULIN RATIO CALCULATED 1.38 Ratio 0.9 - 2
Method :
ALKP - Modified IFCC method
BILD - Vanadate Oxidation
BILT - Vanadate Oxidation
BILI - Derived from serum Total and Direct Bilirubin values
GGT - Modified IFCC method
OT/PT - Derived from SGOT and SGPT values.
SGOT - IFCC* Without Pyridoxal Phosphate Activation
SGPT - IFCC* Without Pyridoxal Phosphate Activation
PROT - Biuret Method
SALB - Albumin Bcg¹method (Colorimetric Assay Endpoint)
SEGB - DERIVED FROM SERUM ALBUMIN AND PROTEIN VALUES
A/GR - Derived from serum Albumin and Protein values

Sample Type : SERUM

PROCESSED AT :
Thyrocare
Hyderabad-500 044

: SELF

UREA (CALCULATED) CALCULATED 23.41 mg/dL Adult : 17-43
BLOOD UREA NITROGEN (BUN) PHOTOMETRY 10.94 mg/dL 7.94 - 20.07
UREA / SR.CREATININE RATIO CALCULATED 45.91 Ratio < 52
CREATININE - SERUM PHOTOMETRY 0.51 mg/dL 0.55-1.02
URIC ACID PHOTOMETRY 4.7 mg/dL 3.2 - 6.1
CALCIUM PHOTOMETRY 9.7 mg/dL 8.8-10.6
BUN / SR.CREATININE RATIO CALCULATED 21.45 Ratio 9:1-23:1
Method :
UREAC - Derived from BUN Value.
BUN - Kinetic UV Assay.
UR/CR - Derived from UREA and Sr.Creatinine values.
SCRE - Creatinine Enzymatic Method
URIC - Uricase / Peroxidase Method
CALC - Arsenazo III Method, End Point.
B/CR - Derived from serum Bun and Creatinine values

Sample Type : SERUM

PROCESSED AT :
Thyrocare
Hyderabad-500 044

(4001043671),SHARMA HEALTHCARE SERVICE ,New
REF. BY : SELF

TOTAL TRIIODOTHYRONINE (T3) E.C.L.I.A 120 ng/dL 80-200
TOTAL THYROXINE (T4) E.C.L.I.A 7.86 µg/dL 4.8-12.7
TSH - ULTRASENSITIVE E.C.L.I.A 5.08 µIU/mL 0.54-5.30
Comments : ***
The Biological Reference Ranges is specific to the age group. Kindly correlate clinically.
Method :
T3,T4 - Fully Automated Electrochemiluminescence Compititive Immunoassay

USTSH - Fully Automated Electrochemiluminescence Sandwich Immunoassay
Disclaimer :Results should always be interpreted using the reference range provided by the laboratory that
performed the test. Different laboratories do tests using different technologies, methods and using different
reagents which may cause difference. In reference ranges and hence it is recommended to interpret result with
assay specific reference ranges provided in the reports. To diagnose and monitor therapy doses, it is recommended
to get tested every time at the same Laboratory.

Sample Type : SERUM
PROCESSED AT :
Thyrocare
Hyderabad-500 044


EST. GLOMERULAR FILTRATION RATE (eGFR) CALCULATED 108 mL/min/1.73 m2
> = 90 : Normal
60 - 89 : Mild Decrease
45 - 59 : Mild to Moderate Decrease
30 - 44 : Moderate to Severe Decrease
15 - 29 : Severe Decrease
Clinical Significance
The normal serum creatinine reference interval does not necessarily reflect a normal GFR for a patient. Because mild and
moderate kidney injury is poorly inferred from serum creatinine alone. Thus, it is recommended for clinical laboratories to routinely
estimate glomerular filtration rate (eGFR), a “gold standard” measurement for assessment of renal function, and report the value
when serum creatinine is measured for patients 18 and older, when appropriate and feasible. It cannot be measured easily in
clinical practice, instead, GFR is estimated from equations using serum creatinine, age, race and sex. This provides easy to
interpret information for the doctor and patient on the degree of renal impairment since it approximately equates to the
percentage of kidney function remaining. Application of CKD-EPI equation together with the other diagnostic tools in renal
medicine will further improve the detection and management of patients with CKD.
Reference
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration
rate. Ann Intern Med. 2009;150(9):604-12.

Method:- CKD-EPI Creatinine Equation

Sample Type : SERUM
Dr Amulya MD (Path)
Labcode : 1912107909/MUW80
PROCESSED AT :
Thyrocare
D-37/1,TTC MIDC,Turbhe,
Navi Mumbai-400 703

: SELF
TEST ASKED : ELEMENTS 22 (TOXIC AND NUTRIENTS),HBA Maharashtra, India,400104
PROFILE,HEMOGRAM

ARSENIC ICP-MS 1.79 µg/L <5
CADMIUM ICP-MS 0.44 µg/L < 1.5
MERCURY ICP-MS 0.66 µg/L <5
LEAD ICP-MS 101.71 µg/L < 150
CHROMIUM ICP-MS 2.28 µg/L < 30
BARIUM ICP-MS 1.31 µg/L < 30
COBALT ICP-MS 0.42 µg/L 0.10 - 1.50
CAESIUM ICP-MS 1.1 µg/L <5
THALLIUM ICP-MS 0.03 µg/L <1
URANIUM ICP-MS 0.03 µg/L <1
STRONTIUM ICP-MS 23.35 µg/L 8 - 38
ANTIMONY ICP-MS 10.53 µg/L 0.10 - 18
TIN ICP-MS 0.2 µg/L <2
MOLYBDENUM ICP-MS 0.82 µg/L 0.70 - 4.0
SILVER ICP-MS 0.44 µg/L <4
VANADIUM ICP-MS 0.56 µg/L < 0.8
BERYLLIUM ICP-MS 0.05 µg/L 0.10 - 0.80
BISMUTH ICP-MS 0.35 µg/L 0.10 - 0.80
SELENIUM ICP-MS 121.79 µg/L 60 - 340
ALUMINIUM ICP-MS 4 µg/L < 30
NICKEL ICP-MS 1.12 µg/L < 15
MANGANESE ICP-MS 13.94 µg/L 7.10 - 20
Method :
ICP - MASS SPECTROMETRY
Note:Reference range has been obtained after considering 95% population as cutoff.

Sample Type : EDTA Whole Blood
Labcode : 2012097697/MUW80 Dr Renuka MD(Path) Dr Arshiya MD(Path)
Barcode : CF428509 Page : 16 of 19

PROCESSED AT :
Thyrocare
Navi Mumbai-400 703

: SELF
TEST ASKED : ELEMENTS 22 (TOXIC AND NUTRIENTS),HBA Mumbai, Maharashtra, India,400104
PROFILE,HEMOGRAM

HbA1c - (HPLC)
H.P.L.C 11.2 %
Bio. Ref. Interval.: As per ADA Guidelines Guidance For Known Diabetics
Below 5.7% : Normal Below 6.5% : Good Control

5.7% - 6.4% : Prediabetic 6.5% - 7% : Fair Control
>=6.5% : Diabetic 7.0% - 8% : Unsatisfactory Control
>8% : Poor Control
Method : Fully Automated H.P.L.C method

AVERAGE BLOOD GLUCOSE (ABG) CALCULATED 275 mg/dL
90 - 120 mg/dl : Good Control
121 - 150 mg/dl : Fair Control
151 - 180 mg/dl : Unsatisfactory Control
> 180 mg/dl : Poor Control
Method : Derived from HBA1c values


Barcode : CF428509
Page : 17 of 19
PROCESSED AT :
Thyrocare
Navi Mumbai-400 703

TEST ASKED : ELEMENTS 22 (TOXIC AND NUTRIENTS),HBA
PROFILE,HEMOGRAM
TEST NAME METHODOLOGY VALUE UNITS Bio. Ref. Interval.

HEMOGLOBIN SLS-Hemoglobin Method 13.6 g/dL 12.0-15.0
Hematocrit (PCV) CPH Detection 46.5 % 36.0-46.0
Total RBC HF & EI 5.09 X 10^6/µL 3.8-4.8
Mean Corpuscular Volume (MCV) Calculated 91.4 fL 83.0-101.0
Mean Corpuscular Hemoglobin (MCH) Calculated 26.7 pq 27.0-32.0
Mean Corp.Hemo. Conc (MCHC) Calculated 29.2 g/dL 31.5-34.5
Red Cell Distribution Width - SD (RDW-SD) Calculated 47 fL 39.0-46.0
Red Cell Distribution Width (RDW - CV) Calculated 13.9 % 11.6-14.0
RED CELL DISTRIBUTION WIDTH INDEX (RDWI) Calculated 249.6 - *Refer Note below
MENTZER INDEX Calculated 18 - *Refer Note below
TOTAL LEUCOCYTE COUNT (WBC) HF & FC 11.98 X 10³ / µL 4.0 - 10.0
DIFFERENTIAL LEUCOCYTE COUNT
Neutrophils Percentage Flow Cytometry 67.6 % 40-80
Lymphocytes Percentage Flow Cytometry 29 % 20-40
Monocytes Percentage Flow Cytometry 2 % 2-10
Eosinophils Percentage Flow Cytometry 0.8 % 1-6
Basophils Percentage Flow Cytometry 0.3 % 0-2
Immature Granulocyte Percentage (IG%) Flow Cytometry 0.3 % 0.0-0.4
Nucleated Red Blood Cells % Flow Cytometry 0.01 % 0.0-5.0
ABSOLUTE LEUCOCYTE COUNT
Neutrophils - Absolute Count Calculated 8.1 X 10³ / µL 2.0-7.0
Lymphocytes - Absolute Count Calculated 3.47 X 10³ / µL 1.0-3.0
Monocytes - Absolute Count Calculated 0.24 X 10³ / µL 0.2 - 1.0
Basophils - Absolute Count Calculated 0.04 X 10³ / µL 0.02 - 0.1
Eosinophils - Absolute Count Calculated 0.1 X 10³ / µL 0.02 - 0.5
Immature Granulocytes (IG) Calculated 0.04 X 10³ / µL 0.0-0.3
Nucleated Red Blood Cells Calculated 0.01 X 10³ / µL 0.0-0.5
PLATELET COUNT HF & EI 344 X 10³ / µL 150-410
Mean Platelet Volume (MPV) Calculated 10.5 fL 6.5-12
Platelet Distribution Width (PDW) Calculated 12.1 fL 9.6-15.2
Platelet to Large Cell Ratio (PLCR) Calculated 29.1 % 19.7-42.4
Plateletcrit (PCT) Calculated 0.36 % 0.19-0.39
Remarks : Alert!!! Predominantly normocytic normochromic with ovalocytes. Platelets:Appear adequate in smear.
*Note - Mentzer index (MI), RDW-CV and RDWI are hematological indices to differentiate between Iron Deficiency Anemia (IDA) and Beta
Thalassemia Trait (BTT). MI >13, RDWI >220 and RDW-CV >14 more likely to be IDA. MI <13, RDWI <220, and RDW-CV <14 more likely
to be BTT. Suggested Clinical correlation. BTT to be confirmed with HB electrophoresis if clinically indicated.
Method : Fully automated bidirectional analyser (6 Part Differential SYSMEX XN-1000)
(Reference : *FC- flowcytometry, *HF- hydrodynamic focussing, *EI- Electric Impedence, *Hb- hemoglobin, *CPH- Cumulative pulse height)
~~ End of report ~~

Barcode : CF428509 Page : 18 of 19
CONDITIONS OF REPORTING
v The reported results are for information and interpretation of the referring doctor only.
v It is presumed that the tests performed on the specimen belong to the patient; named or identified.
v Results of tests may vary from laboratory to laboratory and also in some parameters from time to time for the same
patient.
v Should the results indicate an unexpected abnormality, the same should be reconfirmed.
v Only such medical professionals who understand reporting units, reference ranges and limitations of technologies
should interpret results.
v This report is not valid for medico-legal purpose.
v Neither Thyrocare, nor its employees/representatives assume: (a) any liability, responsibility for any loss or damage
that may be incurred by any person as a result of presuming the meaning or contents of the report, (b) any claims
of any nature whatsoever arising from or relating to the performance of the requested tests as well as any claim for
indirect, incidental or consequential damages. The total liability, in any case, of Thyrocare shall not exceed the
total amount of invoice for the services provided and paid for.
v Thyrocare Discovery video link :- https://youtu.be/nbdYeRgYyQc
EXPLANATIONS
v Majority of the specimen processed in the laboratory are collected by Pathologists and Hospitals we call them
as "Clients".
v Name - The name is as declared by the client and recored by the personnel who collected the specimen.
v Ref.Dr - The name of the doctor who has recommended testing as declared by the client.
v Labcode - This is the accession number in our laboratory and it helps us in archiving and retrieving the data.
v Barcode - This is the specimen identity number and it states that the results are for the specimen bearing
the barcode (irrespective of the name).
v SCP - Specimen Collection Point - This is the location where the blood or specimen was collected as declared by
the client.
v SCT - Specimen Collection Time - The time when specimen was collected as declared by the client.
v SRT - Specimen Receiving Time - This time when the specimen reached our laboratory.
v RRT - Report Releasing Time - The time when our pathologist has released the values for Reporting.
v Reference Range - Means the range of values in which 95% of the normal population would fall.
SUGGESTIONS
v Values out of reference range requires reconfirmation before starting any medical treatment.
v Retesting is needed if you suspect any quality shortcomings.
v Testing or retesting should be done in accredited laboratories.
v For suggestions, complaints, clinical support or feedback, write to us at [email protected]
or call us on 022-3090 0000
+ T&C Apply, #As on 5th December 2024, *As per a survey on doctors' perception of laboratory diagnostics (IJARIIT,2023)
Page : 19 of 19

MUW80O1734624671582_RLS

Uploaded by

Copyright:

Available Formats

MUW80O1734624671582_RLS

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

MUW80O1734624671582_RLS

Uploaded by

Copyright:

Available Formats

Name : Deepika Naik (55Y/F)

Date : 19 Dec 2024

Test Asked : Aarogyam 1.3 With Utsh

Report Status: Complete Report

NAME : DEEPIKA NAIK (55Y/F) SAMPLE COLLECTED AT :

Report Availability Summary

17 Ready 0 Ready with Cancellation 0 Processing 0 Cancelled in Lab

TEST DETAILS REPORT STATUS

AAROGYAM 1.3 WITH UTSH Ready

HIGH SENSITIVITY C-REACTIVE PROTEIN (HS-CRP) Ready

Lipoprotein (a) [Lp(a)] Ready

SERUM COPPER Ready

SERUM ZINC Ready

HBA PROFILE Ready

HEMOGRAM - 6 PART (DIFF) Ready

LIVER FUNCTION TESTS Ready

ELEMENTS 22 (TOXIC AND NUTRIENTS) Ready

IRON DEFICIENCY PROFILE Ready

LIPID PROFILE Ready

VITAMIN D TOTAL AND B12 COMBO Ready

APOLIPROTEIN RATIO Ready

NAME : DEEPIKA NAIK (55Y/F) SAMPLE COLLECTED AT :

NAME : DEEPIKA NAIK (55Y/F) SAMPLE COLLECTED AT :

TEST NAME TECHNOLOGY VALUE UNITS

Normal Levels : <15 µmol/L

Please correlate with clinical conditions.

Sample Collected on (SCT) : 19 Dec 2024 21:40

NAME : DEEPIKA NAIK (55Y/F) SAMPLE COLLECTED AT :

TEST NAME TECHNOLOGY VALUE UNITS

<= 60 years: <= 1.03 mg/L

Please correlate with clinical conditions.

Sample Collected on (SCT) : 19 Dec 2024 21:40

NAME : DEEPIKA NAIK (55Y/F) SAMPLE COLLECTED AT :

TEST NAME TECHNOLOGY VALUE UNITS

25-OH VITAMIN D (TOTAL) E.C.L.I.A 15 ng/mL

Specifications: Precision: Intra assay (%CV):9.20%, Inter assay (%CV):8.50%

Method : Fully Automated Electrochemiluminescence Compititive Immunoassay

Specifications: Intra assay (%CV):2.6%, Inter assay (%CV):2.3 %

Method : Fully Automated Electrochemiluminescence Compititive Immunoassay

Sample Collected on (SCT) : 19 Dec 2024 21:40

Sample Received on (SRT) : 20 Dec 2024 00:51

NAME : DEEPIKA NAIK (55Y/F) SAMPLE COLLECTED AT :

TEST NAME TECHNOLOGY VALUE UNITS

APOLIPOPROTEIN - A1 (APO-A1) IMMUNOTURBIDIMETRY 143 mg/dL

Method : FULLY AUTOMATED RATE IMMUNOTURBIDIMETRY – BECKMAN COULTER

Method : FULLY AUTOMATED RATE IMMUNOTURBIDIMETRY – BECKMAN COULTER

Method : Derived from serum Apo A1 and Apo B values

Sample Collected on (SCT) : 19 Dec 2024 21:40

Sample Received on (SRT) : 20 Dec 2024 00:51

NAME : DEEPIKA NAIK (55Y/F) SAMPLE COLLECTED AT :

TEST NAME TECHNOLOGY VALUE UNITS

< 1.00 - Low Risk

Kit Validation Reference:

Please correlate with clinical conditions.

Sample Collected on (SCT) : 19 Dec 2024 21:40

NAME : DEEPIKA NAIK (55Y/F) SAMPLE COLLECTED AT :

TEST NAME TECHNOLOGY VALUE UNITS

Adults : < 30.0 mg/dl

Kit Validation Reference:

Please correlate with clinical conditions.